Phase 1 N=32 A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers
HIV Infections
Primary: Adverse Events — 0; 0; 0; 0 participants experiencing adverse events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,604 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
Trauma Injury
Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants
Phase 2 N=19 A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Hematologic Malignancy
Primary: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 17 Participants
Phase 3 N=99 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Response Rate (ORR) — 76.7; 0 percentage of participants
N/A N=11 Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
Hypertrichosis
Primary: Comparison of Percent Hair Reduction Between Treatment Arm and Non-treated Control Arm at 12 Weeks Post Final Treatment — 41; 27 percent reduction
N/A N=42 Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal
Tattoo Removal
Primary: Tattoo Clearing at 6 Weeks Post-final Laser Treatment for Each Treatment Arm as Assessed by Blinded Reviewers. — 2.54; 2.17 score on a scale
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=34 Knee Biofeedback Rehabilitation Interface for Game-based Home Therapy for Patients With Knee Osteoarthritis
Osteo Arthritis Knee
Primary: Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) — 3.3; 8.9; 4.6; 9.7 score on a scale — p=<0.05
Phase 2 N=11 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Number of Participants With Objective Response Rate (ORR, Either Partial or Complete Response) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version…
Phase 4 N=265 Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
COVID-19
Primary: 28-days Mortality Rate — 1; 34; 43; 52 Participants — p=<0.001
N/A N=30 AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE
Cholecystitis, Acute
Primary: Number of Days to Resolution of Acute Cholecystitis — 5.30 days
N/A N=49 Feasibility of Exercise and Spinal Cord Injury
Spinal Cord Injuries
Primary: VO2 Peak - Cardiorespiratory Fitness Change (Peak Oxygen Consumption Change) — 14.69; 14.36; 15.61; 13.74 ml/kg/min
Phase 3 N=122 Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty
Total Hip Arthroplasty
Primary: Recovery After Total Hip Arthroplasty — 131.5; 103 score on a scale
Phase 3 N=400 Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)
Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9
Primary: Percentage of Participants Achieving Neutralizing Antibody Seroconversion to Poliovirus Types 1, 2, and 3 at 1 Month Post Dose 3 of IPV — 98.9; 100.0; 98.3; 99.5…
Phase 2 N=130 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission
Primary: Number of Participants With Graft Failure/Rejection — 2; 5 Participants